MetaCap

LENZ Therapeutics Inc. (LENZ)

NASDAQ: LENZHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

2.97-0.375 (-11.23%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

LENZ stock chart

Technical analysis

Key statistics

All statistics
Market cap
$93.16M
EPS (TTM)
-$4.53
Ex-dividend date
Mar 22, 2024
52-week range
2.80 – 32.13
Day range
2.82 – 3.44
Volume / Avg
951.16K / 892.30K
Beta
—

52-week range

$2.80$32.13

LENZ stock today

On Nov 20, LENZ ended the session at $2.97, shedding $0.375 (11.23%), versus the S&P 500's 3.70% decline. Shares are 90.8% below their 52-week high of $32.13, set on Nov 24, 2025 and 5.9% above the 52-week low of $2.80, near the bottom of the past year's range. LENZ is down 81.5% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 90.0%.

LENZ Therapeutics has posted a net loss over the last twelve months (EPS of -$4.53), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About LENZ Therapeutics

Company profile

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Mr. Evert B. Schimmelpennink
Headquarters
Solana Beach, CA
Employees
40
IPO year
2021

Financial highlights

Full financials

In fiscal 2025, LENZ Therapeutics generated $19.1 million in revenue, up 0.0% from fiscal 2024. LENZ Therapeutics reported a net loss of $82.1 million, compared with a loss of $49.8 million a year earlier. Gross margin was 97.8% and operating margin -477.5%.

LENZ Therapeutics annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue$19.09M$0———
Growth—————
Net income$-82.13M$-49.77M$-69.97M$-101.05M$-70.76M
EPS (diluted)$-2.85$-2.34$-35.71$-1.84$-2.45

Analyst forecast

Forecast

Consensus (6 analysts)

none

Avg. price target

$14.83+400.17%

  • Strong buy 0
  • Buy 4
  • Hold 2
  • Sell 0
  • Strong sell 0

Target range

Low $4.00High $45.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Oct 28, 2026
EPS actual vs est.
$-0.99 vs $-0.97
Surprise
-2.06%

Dividends

Dividend history
Annual dividend
$0.00
Last payment
$7.21
Ex-dividend date
Mar 22, 2024

LENZ news

All LENZ news

LENZ Therapeutics peers

Health Care sector
LENZ peer companies
CompanyPrice% ChgMarket capCompare
OTLKOutlook Therapeutics Inc.0.39-2.74%$94.94Mvs LENZ
VYGRVoyager Therapeutics Inc.1.53-4.97%$95.21Mvs LENZ
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs LENZ
ZURAZura Bio Limited Class A0.9305-2.30%$89.63Mvs LENZ
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs LENZ
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs LENZ
BDTXBlack Diamond Therapeutics Inc.1.31-5.76%$75.28Mvs LENZ
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs LENZ

Indexes, lists and sector

LENZ Therapeutics stock FAQ

What is LENZ Therapeutics's stock price today?

LENZ last traded at $2.97 as of Nov 20, 4:00 PM EST, down 11.23% on the day. Prices are delayed at least 15 minutes.

Does LENZ Therapeutics pay a dividend?

Yes. LENZ Therapeutics pays $0.00 per share annually. The most recent dividend of $7.21 had an ex-dividend date of Mar 22, 2024.

Who is LENZ Therapeutics's CEO?

Mr. Evert B. Schimmelpennink is the chief executive officer of LENZ Therapeutics Inc., which has about 40 employees.

Has LENZ ever split its stock?

Yes. The most recent LENZ stock split was a 1-for-7 split on Mar 22, 2024.

What is the LENZ 52-week high?

The 52-week high for LENZ is $32.13 and the 52-week low is $2.80. The stock is currently 90.8% below its high.

Compare LENZ